360 results on '"Suvannasankha, Attaya"'
Search Results
2. Cancer Surveillance in Solid Organ Transplant Recipients With a Pretransplant History of Malignancy: Multidisciplinary Collaborative Expert Opinion
3. Identifying novel mechanisms of biallelic TP53 loss refines poor outcome for patients with multiple myeloma
4. Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study.
5. Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents
6. Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma
7. Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma.
8. DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor + Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple Myeloma
9. Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
10. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
11. Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
12. Nivolumab and daratumumab combination regimens for the treatment of relapsed and refractory multiple myeloma: results of a randomized phase I/II clinical trial
13. OA-27 Single cell transcriptomics reveals the impact of tumor cell interactions with the bone marrow immune microenvironment in the progression of multiple myeloma
14. P-005 Association of baseline soluble BCMA with measures of disease burden and response to linvoseltamab: a comprehensive analysis in patients with relapsed/refractory multiple myeloma (RRMM)
15. OA-32 The impact of genomics to identify novel immunotherapeutic targets in multiple myeloma
16. P-247 Efficacy and safety of linvoseltamab 200 mg in patients with relapsed/refractory multiple myeloma (RRMM): analysis of the LINKER-MM1 study
17. P-240 Efficacy and safety of ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma and prior noncellular anti-BCMA therapy: CARTITUDE-2 cohort C
18. Identifying 1q amplification and PHF19 expressing high-risk cells associated with relapsed/refractory multiple myeloma
19. S197: LINKER-MM1 STUDY: LINVOSELTAMAB (REGN5458) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
20. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
21. Single‐agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM‐2 trial.
22. Supplemental figure legend from Cell Adhesion Molecule CD166 Drives Malignant Progression and Osteolytic Disease in Multiple Myeloma
23. Supplementary Figure 1 from A Noncanonical Flt3ITD/NF-κB Signaling Pathway Represses DAPK1 in Acute Myeloid Leukemia
24. Data from Cell Adhesion Molecule CD166 Drives Malignant Progression and Osteolytic Disease in Multiple Myeloma
25. Supplemental Table 1 from Cell Adhesion Molecule CD166 Drives Malignant Progression and Osteolytic Disease in Multiple Myeloma
26. Supplementary Figure Legend from Temozolomide-Mediated DNA Methylation in Human Myeloid Precursor Cells: Differential Involvement of Intrinsic and Extrinsic Apoptotic Pathways
27. Supplementary Methods, Table 1, Figure Legend 1 from A Noncanonical Flt3ITD/NF-κB Signaling Pathway Represses DAPK1 in Acute Myeloid Leukemia
28. Supplementary Table 1 from Temozolomide-Mediated DNA Methylation in Human Myeloid Precursor Cells: Differential Involvement of Intrinsic and Extrinsic Apoptotic Pathways
29. Supplementary Figure 1 from Temozolomide-Mediated DNA Methylation in Human Myeloid Precursor Cells: Differential Involvement of Intrinsic and Extrinsic Apoptotic Pathways
30. Supplemental figures 1-7 from Cell Adhesion Molecule CD166 Drives Malignant Progression and Osteolytic Disease in Multiple Myeloma
31. Cilta-Cel Efficacy and Safety in Patients with Progressive Multiple Myeloma after Exposure to Non-Cellular Anti-BCMA Immunotherapy
32. Efficacy and Safety of Cilta-Cel in Patients with Progressive Multiple Myeloma after Exposure to Non-Cellular Anti-BCMA Immunotherapy
33. Fingolimod in Combination with Bortezomib Demonstrates Synergistic Tumor Inhibition and Bone Anabolic Effects in Myeloma Bone Disease
34. Patient Derived Xenografts Highlight Mouse-Specific Tumor Evolution Patterns and Genomic Diversity of Multiple Myeloma
35. The Pre-Existing T Cell Landscape Is Associated with Response to High Dose Melphalan and Autologous Stem Cell Transplant in Multiple Myeloma
36. Single-Agent Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma: Final Analysis of the DREAMM-2 Trial
37. Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human Study
38. The Patient Experience with Belantamab Mafodotin: Perspectives of Patients Receiving Treatment in Clinical Trials and in the Real-World
39. Safety and clinical activity of belantamab mafodotin with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-4 Study.
40. A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma
41. GFI1-Dependent Repression of SGPP1 Increases Multiple Myeloma Cell Survival
42. Pre-Transplant M Protein Level Predicts Minimal Residual Disease Status after Autologous Stem Cell Transplantation in Multiple Myeloma
43. Targeted nuclear factor-kappaB suppression enhances gemcitabine response in human pancreatic tumor cell line murine xenografts
44. Belantamab mafodotin for the treatment of relapsed/refractory multiple myeloma in heavily pretreated patients: a US cost-effectiveness analysis
45. P-044 Evaluation of the efficacy and safety of two different linvoseltamab Phase 2 dose regimens: results from LINKER-MM1
46. Comparison of an assumption-free Bayesian approach with Optimal Sampling Schedule to a maximum a posteriori Approach for Personalizing Cyclophosphamide Dosing
47. Deep Vein Thrombosis and Pulmonary Embolism in Cirrhosis Patients
48. Characterizing Muscle Phenotype and Prognosis in Patients with Multiple Myeloma
49. 528 - Cilta-Cel Efficacy and Safety in Patients with Progressive Multiple Myeloma after Exposure to Non-Cellular Anti-BCMA Immunotherapy
50. Validation of a Novel Approach for Dose Individualization in Pharmacotherapy Using Gabapentin in a Proof of Principles Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.